Şizofreni Hastalarında Serum Büyüme Durdurucu Spesifik Protein 6 (Gas-6) Düzeyleri

Amaç: Çalışmamızda atak ve remisyon durumunda olan şizofreni hastaları ile kontrol grubunun serum büyüme durdurucu spesifik protein 6 (GAS-6) düzeylerini ölçerek bu gruplar arasında bir farklılık olup olmadığını araştırdık. Yöntemler: Çalışmamıza İstanbul Üniversitesi Cerrah- paşa Tıp Fakültesi Ruh Sağlığı ve Hastalıkları Anabilim Dalı servisinde yatan; yapılan psikiyatrik muayenesinde DSM-IV-TR tanı kriterlerine göre ş izofreni tanısı konmuş hastalar (N=22) dahil edilmiştir. Hastaların klinik değer- lendirilmeleri psikotik atak ile hastaneye yatırıldığında ve remisyon esnasında Pozitif ve Negatif Sendrom Ölçeği (PANSS) ve Klinik Global İ zlenim Ölçeği (CGI-S) uygu- lanarak yapıldı. Hastaların psikotik atak esnasındaki ve remisyon sırasındaki serum GAS-6 düzeyleri sağlıklı kontrol grubunun düzeyleri ile karşılaştırıldı. Serum GAS- 6 analizleri ticari ELİZA kitleri ile yapılmıştır. Bulgular: Akut psikotik dönem ve remisyon döneminde- ki şizofreni hastalarının ve kontrol grubundaki kişilerin GAS-6 değerleri analiz edildiğinde bu ü ç grup arasında anlamlı bir fark bulunamamıştır. Serum GAS-6 düzeyleri ile PANSS ve CGI-S değerleri arasında herhangi bir kore- lasyon bulunmadığı görülmüştür. Sonuç: GAS-6 ve şizofreni arasındaki ilişkinin daha net olarak ortaya konulabilmesi için antipsikotik ve diğer ilaç kullanımlarının göz önünde bulundurulduğu daha fazla kişinin dahil edildiği kapsamlı çalışmaların yapılmasına ihtiyaç duyulmaktadır

Serum Growth Arrest Speci fic Protein 6 (Gas-6) Levels in Patients with Schizophrenia

Objective: We have investigated serum growth ar- rest-specific protein 6 (GAS-6) levels from patients with schizophrenia divided into acute phase remission phases as well as control group. Methods: This study was conducted in Psychiatry De- partment of Istanbul University Cerrahpasa Medical Fac- ulty. The patients who were diagnosed with schizophrenia after regular psychiatric examination according to DSM- IV criteria (n=22) as well as control subjects were includ- ed in the study. Schizophrenia patients with acute phase and remission phase were evaluated by Positive and Negative Syndrome Scale (PANSS) and Clinical global Impression Scale (CGI-S). The serum GAS-6 levels of schizophrenia patients during acute phase and remission phase were compared with the serum GAS-6 levels of healthy controls. Serum GAS-6 levels were measured by commercial ELISA kits. Results: No difference was found in serum GAS-6 levels among the three groups; schizophrenia with acute phase, schizophrenia with remission phase, and controls. There were no correlations between serum GAS-6 levels and PANSS and CGI scores. Conclusion: To reach a definitive data and better in- terpretation about the relationship between GAS-6 and schizophrenia, future studies with larger groups of pa- tients with schizophrenia subdivided by drug naïve and treated with antipsychotics/other treatment modalities and controls are needed.

Kaynakça

1. Eşsizoğlu A, Yıldırım EA. Ruhsal bozuklukların psikobiyo- lojisinde nitrik oksit. Dicle Med J 2009;1:67-74. 2. Kaya MC, Güneş M, Bulut M, et al. Parmağını ampüte eden bir psikoz olgusu. Dicle Med J 2013;40:109-112. 3. Khandaker GM, Cousins L, Deakin J, et al. Inflammation and immunity in schizophrenia: implications for pathophysiol- ogy and treatment. Lancet Psychiatry. 2015;2:258–270. 4. Müller N, Weidinger E, Leitner B, et al. The role of inflam- mation in schizophrenia. Front Neurosci 2015;9:1-9 5. Gareeva AE, Traks T, Koks S, et al. The role of neurotropins and neuroxins genes in the risk of paranoid schizophrenia in Russian and Tatars. Genetika 2015;51:799–811. 6. Benros ME, Nielsen PR, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for schizo- phrenia: A 30-year population-based register study. Am J Psychiatry 2011;168:1303–1310. 7. Prieto AL, Weber JL, Tracy S, et al. GAS-6, a ligand for the receptor protein-tyrosine kinase Tyro-3, is widely expressed in the central nervous system. Brain Res 1999;816:646– 661. 8. Hsiao FC, Lin YF, Hsieh PS, et al. Circulating growth arrest- specific 6 protein is associated with adiposity, systemic in- flammation, and insulin resistance among overweight and obese adolescents. J Clin Endocrinol Metab 2013;98:267– 274. 9. Wu KS, Hung YJ, Lee CH, et al. The involvement of GAS- 6 signaling in the development of obesity and associated inflammation. Int J Endocrinol 2015;2015:1–7. 10. Ji R, Meng L, Li Q, et al. TAM receptor deficiency af- fects adult hippocampal neurogenesis. Metab Brain Dis 2015;30:633–44. 11. Ji R, Meng L, Jiang X, et al. TAM receptors support neural stem cell survival, proliferation and neuronal differentia- tion. PLoS One. 2014;9:1-16. 12. Ji R, Tian S, Lu HJ, et al. TAM receptors affect adult brain neurogenesis by negative regulation of microglial cell acti- vation. J Immunol. 2013;191:6165–6177. 13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276. 14. Kostakoğlu E, Batur S, Tiryaki A, et al. Reliability and va- lidity of the Turkish version of the Positive and Negative Syndrome Scale (PANSS). Turkish J Psychol 1999;14:23– 34. 15. Guy W. ECDEU Assessment Manual for Psychopharma- cology (028 Clinical Global Impressions [CGI]) Rockville, MD: National Institutes of Health. 1976;218–22. 16. Giangola MD, Yang WL, Rajayer S, et al. Growth arrest- specific protein 6 (GAS-6) protects against renal ischemia/ reperfusion injury. J Surg Res 2015;199:572-579. 17. Sunbul M, Cagman Z, Gerin F, et al. Growth arrest-specific 6 and cardiometabolic risk factors in patients with psoria- sis. Cardiovasc Ther 2015;33:56–61. 18. Erek TA, Bingol OO, Karaca Z, et al. Association of plasma growth arrest-specific protein 6 (GAS-6) concentrations with albuminuria in patients with type 2 diabetes. Ren Fail 2014;36:737–742. 19. Hurtado B, de Frutos PG. GAS-6 in systemic inflam- matory diseases: with and without infection. Crit Care 2010;14:1003. 20. Lutgens E, Tjwa M, De Frutos PG, et al. Genetic loss of GAS-6 induces plaque stability in experimental atheroscle- rosis. J Pathol 2008;216:55–63. 21. Akitake-Kawano R, Seno H, Nakatsuji M, et al. Inhibitory role of GAS-6 in intestinal tumorigenesis. Carcinogenesis 2013;34:1567–1574. 22. Allen KM, Fung SJ, Shannon Weickert C. Cell proliferation is reduced in the hippocampus in schizophrenia. Aust New Zeal J Psychiatry 2015;25:1-8. 23. Dadheech G, Mishra S, Gautam S, et al. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry 2008;50:16–20. 24. Bergink V, Gibney SM, Drexhage H. Autoimmunity, in- flammation, and psychosis: A search for peripheral mark- ers. Biol Psychiatry 2014;75:324–331. 25. Müller N, Riedel M, Schwarz MJ, et al. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005;255:149–151. 26. Tsiperson V, Li X, Schwartz GJ, et al. GAS-6 enhances repair following cuprizone-induced demyelination. PLoS One 2010;5:1–9. 27. Muraki K, Tanigaki K. Neuronal migration abnormalities and its possible implications for schizophrenia. Front Neu- rosci 2015;9:1-10. 28. Augustine K, Rossi RM, Van G, et al. Noninsulin-depen- dent diabetes mellitus occurs in mice ectopically express- ing the human Axl tyrosine kinase receptor. J Cell Physiol 1999;181:433–447. 29. Scroyen I, Frederix L, Lijnen HR. Axl deficiency does not affect adipogenesis or adipose tissue development. Obesity 2012;20:1168–1173. 30. Balogh I, Hafizi S, Stenhoff J, et al. Analysis of GAS-6 in human platelets and plasma. Arterioscler Thromb Vasc Biol 2005;25:1280–1286

Kaynak Göster

1172 719

Arşiv
Sayıdaki Diğer Makaleler

Göğüs Ağrısı Çocuklardaki Malign Tümörlerin İlk Semptomu Olabilir: İki Olgu Sunumu

Alper AKIN, Meki BİLİCİ, MURAT SÖKER, Bedri ALBUDAK, FATİH METEROĞLU

Determination of P-Glycoprotein Expression by Flow Cytometry in Hematological Malignancies

BERKAY SARAYMEN, AYSUN ÇETİN, Behzat ÇİMEN, İHSAN ÇETİN, MUSTAFA YAVUZ KÖKER, Bülent ESER

Clinicohematological Profile of Pancytopenia: A Study from a Tertiary Care Hospital

Monica GUPTA, Abha CHANDNA, Sanjay KUMAR, Sant Prakash KATARİA, Sonia HASİJA, Gajender SINGH, Rajeev SEN

Effects of Intragastric Balloon on Body Mass Index, Lipid Profile and Blood Glucose Regulation: A Prospective Study

Hasan ERDEM, Süleyman ÇETİNKÜNAR, Mehmet AZİRET, Recep AKTİMUR, Sabri ÖZDAŞ, Fahri TETİŞİR, Banu YÜREKLİ

Determining a Safe Time for Oral Intake Following Pediatric Sedation

YUNUS OKTAY ATALAY, CENGİZ KAYA, ERSİN KÖKSAL, Yasemin Burcu ÜSTÜN, LEMAN TOMAK

Gebelerde Üreter Taşı Tedavisinde Üreteroskopi ve Lazer Litotripsi: Tek Merkez Deneyimi

Mustafa Okan İSTANBULLUOĞLU, Hüsnü ALPTEKİN, Hatice IŞIK, İbrahim BULDU

Kolorektal Kanser Cerrahisinde Eksize Edilen Toplam ve Metastatik Lenf Nodu Sayısına Aşırı Kilonun Etkisi

SEZGİN ZEREN, Ceniz KOÇAK, Mehmet Fatih EKİCİ, Şükrü Aydın DÜZGÜN, ZÜLFÜ BAYHAN

The Accuracy of Frozen Section in the Diagnosis of Malignant Adnexal Masses

NURİ YILDIRIM, Alkım Gülşah YILDIRIM ŞAHİNGÖZ, Osman ZEKİOĞLU, Necmettin ÖZDEMİR, Ahmet Mete ERGENOĞLU, Ahmet Özgür YENİEL, M. Coşan TEREK

Frequency of Stent Placement after Ureteroscopic Lithotripsy in a University and a State Hospital

HÜSEYİN ÇELİK, AHMET ÇAMTOSUN, Caner Ediz, İbrahim TOPÇU, RAMAZAN ALTINTAŞ, Cemal TAŞDEMİR

Opinions of Operating Room Nurses Regarding Patient and Staff Safety in Operating Room

Çiğdem SEYMAN CANPOLAT, SULTAN AYAZ ALKAYA